---
title: "\"New Stock Listing\" ALEBUND-B dark market report at 43.36 yuan, nearly 92% above the offering price"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290934711.md"
description: "According to the Economic News Agency on the 26th, ALEBUND-B will be listed next Monday (29th), with the current dark market price reported at HKD 43.36, which is 91.9% higher than the offering price of HKD 22.6 shown by the bank. Calculating based on a board lot of 100 shares, the paper profit per lot is HKD 2,076, excluding handling fees. The current dark market price reported by Yao Cai is HKD 41.5, which is 83.6% higher than the offering price shown by the bank, with a paper profit of HKD 1,890 per lot"
datetime: "2026-06-26T08:20:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290934711.md)
  - [en](https://longbridge.com/en/news/290934711.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290934711.md)
---

# "New Stock Listing" ALEBUND-B dark market report at 43.36 yuan, nearly 92% above the offering price

According to the Economic News Agency report on the 26th, ALEBUND-B (09637) will be listed next Monday (29th). The current price on the Bright Smart dark market is HKD 43.36, which is 91.9% higher than the offering price of HKD 22.6 shown by the firm. Based on a lot of 100 shares, excluding handling fees, the paper profit per lot is HKD 2,076. The current price on the Yuanta dark market is HKD 41.5, which is 83.6% higher than the offering price shown by the firm, with a paper profit of HKD 1,890 per lot

### Related Stocks

- [09637.HK](https://longbridge.com/en/quote/09637.HK.md)
- [01428.HK](https://longbridge.com/en/quote/01428.HK.md)

## Related News & Research

- [Biotech Firms Push Weight-Loss and AI Pipelines Amid Buyback Wave](https://longbridge.com/en/news/291029476.md)
- [Beijing Biostar Wins Shareholder Backing for Capital Mandates and Governance Changes at AGM](https://longbridge.com/en/news/290979536.md)
- [Beijing Biostar Pharmaceuticals files directors list with Hong Kong exchange](https://longbridge.com/en/news/290974298.md)
- [China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds](https://longbridge.com/en/news/290965367.md)
- [Everest Medicines enters China commercialization collaboration with Hainan Herui for budesonide enteric capsules](https://longbridge.com/en/news/290642767.md)